VA Announces National Trial Testing Semaglutide for Alcohol-Use Disorder

The Department of Veterans Affairs has announced a national Phase 3 trial testing whether weekly semaglutide injections can help veterans with moderate or severe alcohol-use disorder reduce or stop drinking. Semaglutide is being studied for this purpose; it is not approved as an alcohol-use-disorder treatment.

VA announced the trial on July 30, 2026, and said recruitment began July 28. The study, called CRAVE — Cessation or Reduction of Alcohol Consumption in Veterans — is planned to involve more than 600 veterans across 18 VA medical centers nationwide.

How the CRAVE trial is designed

Eligible participants are veterans ages 18 to 80 with moderate or severe alcohol-use disorder. Researchers will randomly assign participants to receive weekly injections of semaglutide or a placebo.

The VA announcement describes 24 weeks of injections followed by safety follow-up. The ClinicalTrials.gov record lists an estimated enrollment of 622 participants, a randomized, double-blind, placebo-controlled design, up to 28 weeks of treatment-related study activity and a four-week post-treatment safety assessment.

Researchers plan to track drinking-related outcomes, health and quality-of-life measures. The central question is whether semaglutide itself reduces risky drinking or alcohol-use-disorder symptoms under controlled conditions, rather than whether people taking a GLP-1 drug drink less for other reasons.

Recruitment information is not fully aligned

Veterans should pay attention to a difference between the VA announcement and the federal trial registry. VA describes CRAVE as a national study at 18 medical centers and says recruitment began July 28. The ClinicalTrials.gov record, whose last-posted date is listed as April 15, 2026, still shows the study as “not yet recruiting” and lists one location.

That discrepancy does not by itself establish that either source is wrong. It does mean prospective participants should confirm current site availability with a local VA medical center or through the trial listing before assuming a nearby site is enrolling. The registry identifies VA’s Office of Research and Development as the sponsor.

Why researchers are studying a GLP-1 drug

Semaglutide belongs to a class of medicines known as GLP-1 receptor agonists. The drugs are used for conditions including diabetes and obesity. Researchers are examining whether GLP-1 medicines may also affect brain systems involved in reward and addiction.

A March 2026 cohort study in The BMJ examined U.S. veterans with type 2 diabetes. It found that GLP-1 use was associated with lower risks of alcohol-use disorder and other substance-use outcomes compared with a different diabetes-drug group. Because the study was observational, it could identify an association but could not prove that semaglutide or another GLP-1 drug caused the reduction.

A separate study published online July 22 in Mayo Clinic Proceedings examined 11,258 outpatient adults who drink alcohol, including 256 people who began a GLP-1 receptor agonist. The GLP-1 group had a greater reduction in self-reported weekly alcohol intake, but the difference was no longer statistically significant after researchers adjusted for weight change. The study therefore does not establish that GLP-1 drugs treat alcohol-use disorder.

What veterans should know now

The National Institute on Alcohol Abuse and Alcoholism says evidence-based care for alcohol-use disorder can include behavioral treatment, mutual-support groups and medication. The three medications currently approved by the Food and Drug Administration to help people stop or reduce drinking are naltrexone, acamprosate and disulfiram.

Veterans should not stop existing medication or counseling because of the CRAVE announcement. They also should not use Ozempic, Wegovy or another GLP-1 product on their own to treat alcohol-use disorder. VA advises veterans to consult a health care provider before making treatment changes.

People with severe alcohol-use disorder should seek medical guidance before suddenly stopping alcohol. NIAAA warns that withdrawal after prolonged heavy drinking can be dangerous and, in some cases, life-threatening.

What to watch next

The important next updates will be registry changes showing confirmed recruitment, additional trial locations, enrollment progress, safety information and the eventual randomized results. Until those results are available, semaglutide remains an investigational approach for alcohol-use disorder, not a newly approved VA treatment.

Sources

Look for updates to this story

Discover more from Interactive News

Subscribe to get the latest posts sent to your email.